C11orf82 Polyclonal antibody

C11orf82 Polyclonal Antibody for WB, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human

Applications

WB, ELISA

Conjugate

Unconjugated

Cat no : 27754-1-AP

Synonyms

noxin, Nitric oxide-inducible gene protein, DNA damage-induced apoptosis suppressor protein, DNA Damage Induced Apoptosis Suppressor, DDIAS

---

Validation Data Gallery

• 

  WB analysis using 27754-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 27754-1-AP (C11orf82 antibody) at dilution of 1:1000 incubated at room temperature for 1.5 hours.

---

Tested Applications

• Positive WB detected in: HepG2 cells, K-562 cells, NCI-H1299 cells

Recommended dilution

• Western Blot (WB): WB : 1:500-1:2000

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, Check data in validation data gallery.

Product Information

27754-1-AP targets C11orf82 in WB, ELISA applications and shows reactivity with human samples.

• Tested Reactivity: human
• Host / Isotype: Rabbit / IgG
• Class: Polyclonal
• Type: Antibody
• Immunogen: C11orf82 fusion protein Ag26829
• Full Name: chromosome 11 open reading frame 82
• Observed Molecular Weight: 120 kDa
• GenBank Accession Number: BC039268
• Gene Symbol: C11orf82
• Gene ID (NCBI): 220042
• Conjugate: Unconjugated
• Form: Liquid
• Purification Method: Antigen affinity purification
• Storage Buffer: PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
• Storage Conditions: Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20^oC storage. 20ul sizes contain 0.1% BSA.

Background Information

DNA damage-induced apoptosis suppressor (DDIAS) is an oncogenic protein that is highly expressed in several cancers, including colorectal, lung, breast, and hepatocellular carcinoma (HCC), and stimulates cancer cell proliferation and cell cycle progression.DDIAS protects cancer cells from DNA damage reagents and tumor necrosis factor-associated apoptosis-inducing ligands (TRAILs) and positively regulates cancer cell invasion by stabilizing the β- catenin positively regulates cancer cell invasion. Therefore, DDIAS is considered as a potential therapeutic target for malignant lung cancer.